MIN-101 phase 2b, results due in Q4

News
1

Minerva Neurosciences, Inc (NASDAQ:NERV) said its expects to report results from a phase 2b trial with its schizophrenia drug candidate and it’s looking to begin clinical trials with a medicine for major depression next year. The Waltham, Massachusetts-based company said on Monday the last patient completed the 24-week open-label extension period of the phase 2b clinical trial of the drug MIN-101 for patients with negative symptoms of schizophrenia.

http://www.kentuckypostnews.com/minerva-expects-to-report-results-from-schizophrenia-drug-in-q4-depression-drug-trials-to-start-next-year-nasdaqnerv/189450/

2 Likes